Press Releases

 
Press Releases
  Date Title and Summary View
May 10, 2017
CRANBURY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, N...
PDF
May 9, 2017
100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EU On Target to Reach 300 Patients on Galafold by Year-End 2017 Additional Important Phase 1/2 Pompe Clinical Data Expected in 2Q17 and 3Q17 Phase 3 EB Topline Data on Track for 3Q17 CRANBURY, N.J., May 09, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD)...
PDF
May 2, 2017
CRANBURY, N.J., May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2017. The call wil...
PDF
May 2, 2017
CRANBURY, N.J. and PARIS, May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in France following the publication of the price in the Official Journal. Galafold is now reimbursed in Fr...
PDF
Apr 6, 2017
CRANBURY, N.J., April 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, is supporting several activities during Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who...
PDF
Apr 3, 2017
Target Exceeded with More than 160 Patients Enrolled Top-Line Data on Track for 3Q17 CRANBURY, N.J., April 03, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, has completed enrollment in the ongoing Phase 3 clinical study (ESSENCE) of the ...
PDF
Mar 8, 2017
CRANBURY, N.J. and MILAN, Italy, March 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the precision medicine Galafold in Italy following the final publication of reimbursement guidelines by the Ministry of Health (M...
PDF
Mar 2, 2017
CRANBURY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that management will present at two upcoming investor conferences. John Crowley, Chairman and Chief Executive Officer, will present at the Cowen & Com...
PDF
Mar 1, 2017
Growing Momentum for EU Galafold (Migalastat) Launch for Fabry Disease Tracking Toward 300 Patients by Year-End 2017  Target Enrollment Achieved in Phase 1/2 Pompe Study - Additional Data Expected in 2Q17 and 3Q17 Phase 3 EB Program Remains on Track for Topline Data in Mid-2017 CRANBURY, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Amicus Ther...
PDF
Feb 27, 2017
National Institute for Health and Care Excellence (NICE) Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease CRANBURY, N.J., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has commenced the commercial launch of the pr...
PDF
Page: FirstPrevious
3
... NextLast